孟鲁司特钠联合奥洛他定治疗慢性荨麻疹患者的效果

Effects of Montelukast sodium combined with Olopatadine in treatment of patients with chronic urticaria

目的:观察孟鲁司特钠联合奥洛他定治疗慢性荨麻疹患者的效果。方法:选取2022年1月至2023年6月该院收治的70例慢性荨麻疹患者进行前瞻性研究,根据抽签法将其分为对照组和观察组各35例。对照组采取奥洛他定治疗,观察组在对照组基础上联合孟鲁司特钠治疗,比较两组临床症状评分、治疗前后炎性因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白三烯E4(LTE4)、嗜酸性粒细胞比例]水平、临床症状消失时间、Th1/Th2细胞因子[γ干扰素(IFN-γ)和白细胞介素-4(IL-4)]水平、临床疗效和不良反应发生率。结果:治疗后,观察组瘙痒、风团数目、风团平均直径评分均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组hs-CRP、TNF-α、IL-6、LTE4水平和嗜酸性粒细胞比例均低于对照组,差异有统计学意义(P<0.05);观察组瘙痒、风团、血管性水肿等临床症状消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,观察组IL-4水平低于对照组,IFN-γ水平高于对照组,差异均有统计学意义(P<0.05);观察组治疗总有效率为91.43%(32/35),高于对照组的68.57%(24/35),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合奥洛他定治疗慢性荨麻疹患者可提高治疗总有效率,改善Th1/Th2细胞因子水平,缩短临床症状消失时间,降低临床症状评分和炎性因子水平,效果优于单纯奥洛他定治疗。

Objective:To observe effects of Montelukast sodium combined with Olopatadine in treatment of patients with chronic urticaria.Methods:A prospective study was conducted on 70 patients with chronic urticaria admitted to this hospital from January 2022 to June 2023.According to the lottery method,they were divided into control group and observation group,35 cases in each group.The control group was treated with Olopatadine,while the observation group was treated with Montelukast sodium on the basis of that of the control group.The clinical symptom scores,the levels of inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),leukotriene E4(LTE4),eosinophil ratio]before and after the treatment,the disappearance time of clinical symptoms,the levels of Th1/Th2 cytokines[interferon-γ(IFN-γ)and interleukin-4(IL-4)],the clinical efficacy,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the scores of pruritus,number of wheals a nd average diameter of wheals in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of hs-CRP,TNF-α,IL-6,LTE4 and the proportion of eosinophils in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The disappearance time of clinical symptoms such as itching,wheal and vascular edema in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the level of IL-4 in the observation group was lower than that in the control group,the level of IFN-γwas higher than that in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 91.43%(32/35),which was higher than 68.57%(24/35)in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions betw een the two groups(P>0.05).Conclusions:Montelukast sodium combined with Olopatadine in the treatment of the patients with chronic urtic aria can improve the total effective rate of treatment,improve the levels of Th1/Th2 cytokines,shorten the disappearance time of clinical symptoms,and reduce the clinical symptom scores and the inflammatory factor levels.Moreover,it is superior to single Olopatadine treatment.